Abstract
Low-temperature plasma (LTP) has emerged as a groundbreaking method for inducing immunogenic cell death (ICD) in cancer cells. ICD is a form of cellular demise that triggers an immune response against malignant cells. LTP has demonstrated remarkable potential in activating the immune system and augmenting antitumor responses. In this study, we delved into the capacity of LTP to induce ICD and explored its impact on the immune system. Additionally, we assessed the therapeutic effects of LTP-induced ICD on the immune system within a melanoma tumor model. The LTP treated B16F10 (LTP-B16) showed a notable surge in CD8+T cells accompanied by enhanced expression of granzyme B and IFN-γ, and reduction in Treg cells. This study ingeniously amalgamated LTP-induced ICD with cisplatin to synergistically impede tumor growth. These results offer fresh perspectives for the creation of tumor vaccines based on LTP as well as a new approach for therapeutic tumor immunotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
